At a glance
ClinicalIndex Comparison RecordN/ACompleted· 102 enrolled
Drug / intervention
sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Effectiveness of Second-Line Sunitinib Following Immune-oncologic (IO) Therapy in Patients With Metastatic Renal Cell Carcinoma in the International Metastatic Renal Cell Carcinoma Database (IMDC)
In Brief
An observational study evaluating sunitinib for Metastatic Renal Cell Carcinoma (mRCC). Completed, enrolled 102 participants across 1 site.
Detailed Summary
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma (mRCC)
CountriesCanada
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedNov 25, 2019
Enrollment StartOct 31, 2019
Primary CompletionMar 9, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.6 years ago
Interventions
sunitinibdrug
Patients to receive sunitinib as second line therapy for mRCC